drugset / Trial / NCT00404612

A Study of LX211 in Active Sight Threatening, Non-infectious Intermediate-, Anterior and Intermediate-, Posterior-, or Pan-Uveitis

NCT00404612

Phase 3 Completed 218 enrolled Lux Biosciences, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The objective of this study is to evaluate the safety and efficacy of LX211 as therapy in subjects with active non-infectious uveitis

Timeline

Start
2007-01
Primary completion
2008-11
Completion
2009-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator Voclosporin Other / unclassified 0.2 mg/kg
Comparator Voclosporin Other / unclassified 0.4 mg/kg
Comparator Voclosporin Other / unclassified 0.6 mg/kg